CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply.

Fennell, Dean A; Griffiths, Gareth; Ottensmeier, Christian; Hanna, Gerard G; Danson, Sarah; Szlosarek, Peter; Nye, Mavis

Fennell, Dean A; Griffiths, Gareth; Ottensmeier, Christian; Hanna, Gerard G; Danson, Sarah; Szlosarek, Peter; Nye, Mavis.

Afiliação

Fennell DA; Leicester Cancer Research Centre, University of Leicester, Leicester, UK. Electronic address: df132@le.ac.uk.
Griffiths G; Cancer Research UK Southampton Clinical Trials Unit, University of Southampton, Southampton, UK.
Ottensmeier C; Clatterbridge Cancer Centre NHS Foundation trust, University of Liverpool, Liverpool, UK.
Hanna GG; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia; Queen's University Belfast, Belfast, UK.
Danson S; Weston Park Cancer Centre, University of Sheffield, Sheffield, UK.
Szlosarek P; Cancer Research UK Barts Centre, Queen Mary University of London, London, UK.
Nye M; Mavis Nye Foundation, London, UK.

Lancet Oncol ; 23(1): e14-e15, 2022 01.

Article em En | MEDLINE | ID: mdl-34973224

Assuntos

Mesotelioma Maligno; Mesotelioma; Humanos; Imunoterapia/efeitos adversos; Mesotelioma/tratamento farmacológico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mesotelioma Maligno / Mesotelioma Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google